| P50 | author | Rino Rappuoli | Q2154243 |
| P2093 | author name string | Steven Black | |
| | Paul Henri Lambert | |
| P2860 | cites work | RNA vaccines in cancer treatment | Q21296852 |
| | Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer | Q24632187 |
| | Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team | Q28239113 |
| | Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures | Q28286437 |
| | Systems biology: a brief overview | Q29547514 |
| | Molecular and cellular signatures of human vaccine adjuvants. | Q30370898 |
| | Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. | Q30380578 |
| | Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis. | Q30383270 |
| | A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells | Q33459148 |
| | A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines | Q33488775 |
| | The prime-boost strategy: exciting prospects for improved vaccination | Q33876983 |
| | Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. | Q33885483 |
| | Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group | Q33896897 |
| | Reverse vaccinology, a genome-based approach to vaccine development | Q33938845 |
| | Effect of pneumococcal conjugate vaccine on pneumococcal meningitis | Q34015633 |
| | Shared paramyxoviral glycoprotein architecture is adapted for diverse attachment strategies | Q34139647 |
| | Multi-locus sequence typing: a tool for global epidemiology | Q34269596 |
| | Impact of meningococcal C conjugate vaccine in the UK. | Q34927684 |
| | Smallpox vaccination: a review, part II. Adverse events | Q35175732 |
| | MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile | Q35192178 |
| | Vaccination and autoimmune disease: what is the evidence? | Q35590061 |
| | Vaccine policy changes and epidemiology of poliomyelitis in the United States | Q35916018 |
| | Post-genomic vaccine development | Q36485259 |
| | Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels | Q37106916 |
| | Group A streptococcal infections and acute rheumatic fever | Q37244856 |
| | Principles of vaccine design-Lessons from nature | Q37780346 |
| | Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. | Q38313431 |
| | A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children. | Q38346472 |
| | Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial | Q39480891 |
| | The next decade of vaccines: societal and scientific challenges | Q39740365 |
| | AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity | Q39782280 |
| | The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment | Q40669531 |
| | Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains | Q40806866 |
| | Immunization against diphtheria with special emphasis on immunization of adults | Q41141121 |
| | Pregnancy and H1N1 infection. | Q43174638 |
| | Infectious disease. Costs of meningitis outbreaks are crippling, too. | Q43932142 |
| | Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials | Q44324590 |
| | Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae--and associated interactions with Staphylococcus aureus and Haemophilus influenzae colonization--in HIV-Infected and HIV-uninfected childre | Q44702826 |
| | Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial | Q44920056 |
| | A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. | Q45788200 |
| | Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission | Q45839365 |
| | Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects | Q46197462 |
| | Evidence for autoimmune antibodies directed against embryonic neural cell adhesion molecules (N-CAM) in patients with group B meningitis | Q48907979 |
| | Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. | Q50739879 |
| | Bacterial lipoproteins differentially regulate human primary and memory CD4+ T and B cell responses to pneumococcal protein antigens through Toll-like receptor 2. | Q51057635 |
| | Immunologic response of man to group B meningococcal polysaccharide vaccines. | Q54484873 |
| | Global Eradication of Smallpox | Q56814341 |
| | Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada | Q77442261 |
| | Rabies vaccine freed of the factor causing allergic encephalitis | Q80310137 |
| P433 | issue | 9788 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 360-368 | |
| P577 | publication date | 2011-06-12 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Vaccine discovery and translation of new vaccine technology | |
| P478 | volume | 378 | |